V940 + Pembrolizumab + Chemotherapy for Lung Cancer

(INTerpath-13 Trial)

This trial tests a new treatment called V940, which aims to help the immune system combat squamous non-small cell lung cancer that has spread. Researchers seek to determine if V940, combined with pembrolizumab (an immunotherapy drug) and chemotherapy, can extend patients' lives and prevent cancer growth compared to a placebo. Individuals who have not received treatment for their metastatic lung cancer may be suitable candidates for this study. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, providing an opportunity to contribute to significant advancements in cancer care.

The trial information does not specify if you need to stop taking your current medications. However, if you are on chronic steroid therapy or immunosuppressive therapy, you may need to stop or adjust it before starting the study treatment.

Research has shown that V940, when combined with pembrolizumab, appears safe based on previous studies. This combination has been tested in patients with various cancer types and has been well-tolerated in past research. Some patients experienced side effects, mostly mild, such as tiredness and flu-like symptoms.

Pembrolizumab is already approved for treating various cancers and is generally considered safe. Most people tolerate it well, though some might experience side effects like fatigue or skin reactions.

Researchers are excited about V940 in combination with pembrolizumab and chemotherapy for lung cancer because it introduces a novel element to treatment. V940 is a personalized cancer vaccine that aims to boost the immune system's ability to recognize and attack cancer cells more effectively. This is different from traditional treatments like chemotherapy and immune checkpoint inhibitors, which can sometimes struggle to specifically target cancer cells. The combination of V940 with pembrolizumab, an immune checkpoint inhibitor, could enhance the overall immune response, potentially leading to better outcomes for patients.

In this trial, participants will receive either V940 with pembrolizumab and chemotherapy or a placebo with pembrolizumab and chemotherapy. Research has shown that V940, when combined with pembrolizumab, may help treat certain cancers. In an earlier study, 74.8% of patients who received both V940 and pembrolizumab remained cancer-free after 2.5 years, compared to 55.6% of those who only received pembrolizumab. This indicates that more patients stayed cancer-free longer with the combination. V940 enhances the immune system's ability to target cancer cells, potentially leading to better treatment results. Evidence suggests this combination might improve outcomes for people with lung cancer, but further research is needed to confirm its effectiveness.¹²⁶⁷⁸